David A. Siegel Global Blood Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $26.5 Million - $55.8 Million	818,800 Added 245.08%	1,152,900 $78.5 Million
Q2 2022 Aug 15, 2022	BUY	$22.3 - $37.39 $5.48 Million - $9.19 Million	245,900 Added 278.8%	334,100 $10.7 Million
Q1 2022 May 16, 2022	BUY	$25.68 - $35.59 $2.26 Million - $3.14 Million	88,200 New	88,200 $3.06 Million
Q3 2020 Nov 16, 2020	SELL	$52.76 - $74.49 $511,772 - $722,553	-9,700 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$48.73 - $81.82 $311,872 - $523,647	-6,400 Reduced 39.75%	9,700 $612,000
Q1 2020 May 15, 2020	SELL	$41.72 - $87.2 $2.68 Million - $5.6 Million	-64,196 Reduced 79.95%	16,100 $823,000
Q4 2019 Feb 14, 2020	BUY	$45.7 - $81.86 $3.67 Million - $6.57 Million	80,296 New	80,296 $6.38 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.